Theravance & Mylan v. Eugia et al. — YUPELRI Patent Dispute Resolved in 17 Days
Theravance Biopharma and Mylan filed suit in January 2024 against ten generic pharmaceutical companies seeking to block ANDA-based entry of generic revefenacin inhalation solution. The case against Orbicular closed just 17 days after filing, with a stipulated consent injunction barring Orbicular from commercialising its ANDA product until US11858898B2 expires.
17-day ANDA patent closure with injunction blocking Orbicular’s generic revefenacin
Filed on 9 January 2024 in the District of New Jersey, this case pits Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc., Theravance Biopharma Ireland Limited, Mylan Ireland Limited, and Mylan Specialty, L.P. collectively against ten generic pharmaceutical defendants. The core dispute concerns U.S. Patent No. 11,858,898B2, which covers revefenacin inhalation solution — sold under the brand name YUPELRI® — a once-daily, nebulised long-acting muscarinic antagonist (LAMA) approved for COPD maintenance treatment.
The action was partially resolved on 26 January 2024 through a Stipulated Consent Judgment and Injunction entered solely as between the plaintiffs and defendant Orbicular Pharmaceutical Technologies Private Limited. All claims, counterclaims, and affirmative defenses between those parties were dismissed without prejudice, while Orbicular accepted an injunction prohibiting it — and anyone acting on its behalf — from making, using, offering to sell, selling, or importing the ANDA No. 217868 product in the United States until US11858898B2 expires. The FDA retains authority to grant final ANDA approval at any time, but commercial launch remains blocked.
Resolution in 17 days is exceptionally fast even by ANDA Hatch-Waxman standards, suggesting pre-litigation negotiations were already well advanced when the complaint was filed, or that Orbicular assessed its infringement exposure and chose rapid settlement over costly litigation. The without-prejudice dismissal technically preserves both parties’ right to re-litigate, though the injunction renders this largely academic for Orbicular while the patent stands. The public record does not reveal whether a licensing arrangement accompanies the injunction, nor does it disclose the expected expiry date of US11858898B2 or the status of the remaining nine defendants.
Filing to voluntary dismissal in 17 days
17 days — among the fastest closures in ANDA patent litigation
Dismissed without prejudice — consent injunction blocks Orbicular’s ANDA launch
Stipulated Consent Judgment — agreed court order, not a trial ruling
A stipulated consent judgment is a binding court order negotiated and signed by both parties, then entered by the court without a merits hearing. Here it simultaneously achieves dismissal of the litigation and imposes an injunction on Orbicular. Because the court retains jurisdiction to enforce it, Orbicular’s compliance is court-supervised — any breach would constitute contempt, not merely a breach of contract.
Enforceable by contemptDismissed without prejudice — but the injunction overrides the practical difference
A without-prejudice dismissal theoretically allows either party to refile the same claims. A with-prejudice dismissal would bar refiling permanently. The public record here is silent on which outcome was preferred — the without-prejudice framing simply preserves optionality. In practice, however, the accompanying injunction already achieves the plaintiffs’ core objective: Orbicular cannot commercialise its ANDA product while US11858898B2 remains in force, making refiling unlikely to be necessary.
Injunction renders refiling mootHow Hatch-Waxman shapes this outcome
Under the Hatch-Waxman Act, a generic manufacturer filing an ANDA with a Paragraph IV certification triggers an automatic 30-month stay on FDA approval once the brand holder sues within 45 days. The consent injunction here goes further — it blocks Orbicular’s commercial launch not just during a stay period but until patent expiry. FDA may still grant technical approval of ANDA No. 217868, but approval alone does not translate to lawful US market entry while the injunction holds.
Post-approval launch still blockedTen defendants filed simultaneously — Orbicular resolved first
Theravance and Mylan named ten separate generic entities spanning Eugia, Lupin, Cipla, Aurobindo, Mankind, and Lifestar alongside Orbicular — a standard ANDA litigation tactic to consolidate all Paragraph IV challenges in a single action. Orbicular’s rapid settlement suggests it may have had the weakest non-infringement or invalidity position among the group. The remaining nine defendants’ cases are presumed ongoing, and their outcomes could materially affect the patent’s enforceability across the generic landscape.
Nine defendants still activeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Theravance Biopharma R & D IP, LLC | Company | Pharmaceutical IP holding & commercialisation group — holder of US11858898B2 (YUPELRI®)Search in Eureka ↗ |
| Defendant | Eugia Pharma Specialities, Ltd. | Company | Indian generic pharmaceutical manufacturer seeking US market entry via ANDA No. 217868Search in Eureka ↗ |
| Plaintiff counsel | Arnold B. Calmann | Attorney | Counsel for Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | New Jersey District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulation is notable for what it achieves beyond mere dismissal: by embedding an injunction directly into the consent order, plaintiffs secured court-enforceable market exclusion without a merits ruling. The phrase ‘anyone acting on behalf of Orbicular’ extends the injunction beyond the corporate entity to potential sublicensees or contract manufacturers. The court’s retained jurisdiction clause ensures ongoing supervision, converting what might otherwise be a private settlement into a judicially enforceable instrument. Each party bearing its own costs suggests neither side conceded wrongdoing.
US11858898B2 — revefenacin inhalation solution (YUPELRI®)
U.S. Patent No. 11,858,898B2 (application no. US18/199812) protects revefenacin inhalation solution — a once-daily, nebulised long-acting muscarinic antagonist (LAMA) indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD). The patent is held by Theravance Biopharma R&D IP, LLC and forms the principal IP barrier protecting YUPELRI®, the first once-daily, nebuliser-delivered LAMA approved by the FDA. The high B2 grant number suggests a relatively recent issuance, consistent with a lifecycle management or continuation filing strategy common in branded respiratory drug IP.
Revefenacin occupies a distinct niche in the inhaled COPD market — the only approved LAMA formulated specifically for standard jet nebulisers, making it relevant to patients unable to use dry powder or pressurised MDI devices. This clinical differentiation translates into meaningful commercial exclusivity. The simultaneous filing against ten ANDA applicants underscores how actively Theravance and Mylan are defending this IP position. Any generic entrant seeking to commercialise a nebulised muscarinic antagonist for COPD should treat US11858898B2 as a primary freedom-to-operate concern.
Should your team run an FTO against US11858898B2?
If your organisation is developing or filing an ANDA for any nebulised LAMA or revefenacin-based inhalation product, US11858898B2 is a mandatory FTO checkpoint. This case confirms the patent is actively enforced and that plaintiffs will move within days of an ANDA filing to secure injunctive relief. Formulation teams working on alternative nebulised bronchodilators should also assess claim scope carefully — muscarinic antagonist chemistry and nebuliser-compatible excipient combinations may fall within the patent’s claims even where the active molecule differs.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US11858898B2 against your product specification in minutes, identifying design-around opportunities or freedom corridors before you commit to an ANDA filing. Eureka’s claim monitoring alerts will notify your team if continuation patents from the same family are granted — a critical signal for any branded respiratory product with remaining commercial runway.
Run a freedom-to-operate analysis on US11858898B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases in inhaled respiratory therapeutics
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the COPD inhalation therapy IP landscape
A 17-day resolution with injunction shows Theravance and Mylan are moving fast to wall off generic entry into the YUPELRI® market.
Speed of resolution signals aggressive Hatch-Waxman enforcement posture
Filing against ten defendants simultaneously and securing an injunction against one within 17 days is consistent with a coordinated brand-protection strategy. Competitors and generic filers in the revefenacin space should expect similar rapid enforcement action. Early settlement typically indicates either strong patent claims or a defendant with limited litigation budget — both outcomes favour the brand holder.
ANDA No. 217868 blocked — but eight other ANDA filers remain in play
Orbicular’s injunction removes one generic pathway, but Lupin, Cipla, Aurobindo, Eugia, Mankind, Lifestar, and associated entities are still active defendants. Any invalidity or non-infringement finding in those parallel proceedings could undermine the injunction’s practical value and open the US market to generic revefenacin regardless of Orbicular’s settlement.
Theravance v Eugia — key questions answered
The case against Orbicular Pharmaceutical Technologies was dismissed without prejudice on 26 January 2024 via a Stipulated Consent Judgment and Injunction. Orbicular was enjoined from commercialising ANDA No. 217868 (generic YUPELRI®) in the US until US11858898B2 expires. Each party bore its own costs. The case against the remaining nine defendants was not resolved by this stipulation.
US11858898B2 (application US18/199812) covers revefenacin inhalation solution, the active pharmaceutical ingredient in YUPELRI® — a once-daily nebulised long-acting muscarinic antagonist (LAMA) approved for COPD maintenance treatment. It is held by Theravance Biopharma R&D IP, LLC and was actively enforced against at least ten generic ANDA filers in this 2024 litigation.
The public record does not specify the parties’ reasons for choosing a without-prejudice dismissal. In ANDA consent judgments, without-prejudice terms are sometimes used to preserve optionality for both sides. Here, however, the accompanying injunction blocking Orbicular’s ANDA launch until patent expiry achieves the plaintiffs’ primary commercial objective, making the prejudice distinction largely academic in practice.
The consent injunction is court-enforceable and bars Orbicular — and anyone acting on its behalf — from making, using, offering to sell, selling, or importing the ANDA No. 217868 product in the US until US11858898B2 expires. Unlike a purely contractual settlement, breach of a consent injunction constitutes contempt of court. The court retained jurisdiction to enforce the order, meaning plaintiffs have a fast judicial remedy if Orbicular violates its terms.
The defendants are Eugia Pharma Specialities Ltd., Orbicular Pharmaceutical Technologies Private Limited, Eugia US LLC, Mankind Pharma Ltd., Lupin Ltd., Lupin Pharmaceuticals Inc., CIPLA USA Inc., Cipla Limited, Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., and Lifestar Pharma LLC. All defendants filed ANDAs seeking approval to market generic versions of YUPELRI® (revefenacin) inhalation solution for oral inhalation.
PatSnap Eureka searches patents and litigation data to answer instantly.